These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36816363)

  • 1. M6A Promotes Colorectal Cancer Progression via Regulating the miR-27a-3p/BTG2 Pathway.
    Liu W; Zhang Z; Luo X; Qian K; Huang B; Deng J; Yang C
    J Oncol; 2023; 2023():7097909. PubMed ID: 36816363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA ADAMTS9-AS2 inhibits cell proliferation and decreases chemoresistance in clear cell renal cell carcinoma via the miR-27a-3p/FOXO1 axis.
    Song EL; Xing L; Wang L; Song WT; Li DB; Wang Y; Gu YW; Liu MM; Ni WJ; Zhang P; Ma X; Zhang X; Yao J; Chen Y; An RH
    Aging (Albany NY); 2019 Aug; 11(15):5705-5725. PubMed ID: 31400752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulated lncRNA ADAMTS9-AS2 suppresses progression of lung cancer through inhibition of miR-223-3p and promotion of TGFBR3.
    Liu C; Yang Z; Deng Z; Zhou Y; Gong Q; Zhao R; Chen T
    IUBMB Life; 2018 Jun; 70(6):536-546. PubMed ID: 29707897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis.
    Ren N; Jiang T; Wang C; Xie S; Xing Y; Piao D; Zhang T; Zhu Y
    Aging (Albany NY); 2020 Jun; 12(11):11025-11041. PubMed ID: 32516127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADAMTS9-AS2 regulates PPP1R12B by adsorbing miR-196b-5p and affects cell cycle-related signaling pathways inhibiting the malignant process of esophageal cancer.
    Chen Z; Tang W; Ye W; Song L; Chen Z
    Cell Cycle; 2022 Aug; 21(16):1710-1725. PubMed ID: 35503407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. lncRNA RMST suppresses the progression of colorectal cancer by competitively binding to miR-27a-3p/RXRα axis and inactivating Wnt signaling pathway.
    Chen S; Ji L; Wang Y; Zhang L; Xu M; Su Y; Zhang X
    Acta Biochim Biophys Sin (Shanghai); 2023 May; 55(5):726-735. PubMed ID: 37246895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA ADAMTS9-AS2 promotes tongue squamous cell carcinoma proliferation, migration and EMT via the miR-600/EZH2 axis.
    Li Y; Wan Q; Wang W; Mai L; Sha L; Mashrah M; Lin Z; Pan C
    Biomed Pharmacother; 2019 Apr; 112():108719. PubMed ID: 30970517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-27a-3p Reverses Adriamycin Resistance by Targeting BTG2 and Activating PI3K/Akt Pathway in Breast Cancer Cells.
    Zhu B; Chen W; Fu Y; Cui X; Jin L; Chao J; Yun X; Gao P; Shan S; Li J; Yin X; Zhu C; Qin X
    Onco Targets Ther; 2020; 13():6873-6884. PubMed ID: 32764979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review on the role of ADAMTS9-AS2 in different disorders.
    Ghafouri-Fard S; Askari A; Hussen BM; Baniahmad A; Taheri M; Mokhtari M
    Pathol Res Pract; 2023 Mar; 243():154346. PubMed ID: 36746036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LINC01089 inhibits the progression of cervical cancer via inhibiting miR-27a-3p and increasing BTG2.
    Li S; Han Y; Liang X; Zhao M
    J Gene Med; 2021 Jan; 23(1):e3280. PubMed ID: 33025678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA ADAMTS9-AS2 regulates ovarian cancer progression by targeting miR-182-5p/FOXF2 signaling pathway.
    Wang A; Jin C; Li H; Qin Q; Li L
    Int J Biol Macromol; 2018 Dec; 120(Pt B):1705-1713. PubMed ID: 30268751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of lncRNA ADAMTS9-AS2 Promotes Salivary Adenoid Cystic Carcinoma Metastasis via PI3K/Akt and MEK/Erk Signaling.
    Xie S; Yu X; Li Y; Ma H; Fan S; Chen W; Pan G; Wang W; Zhang H; Li J; Lin Z
    Mol Ther; 2018 Dec; 26(12):2766-2778. PubMed ID: 30217729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-27a-3p functions as an oncogene in gastric cancer by targeting BTG2.
    Zhou L; Liang X; Zhang L; Yang L; Nagao N; Wu H; Liu C; Lin S; Cai G; Liu J
    Oncotarget; 2016 Aug; 7(32):51943-51954. PubMed ID: 27409164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2.
    Chen L; Li Z; Hu S; Deng Q; Hao P; Guo S
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):217-229. PubMed ID: 35039898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Overexpression of the long non-coding RNA ADAMTS9-AS2 suppresses colorectal cancer proliferation and metastasis].
    Bu X; Qin A; Luo Z; Hu Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Jul; 44(7):741-748. PubMed ID: 31413211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oncogenic miR-27a/BTG2 axis promotes obesity-associated hepatocellular carcinoma by mediating mitochondrial dysfunction.
    Su Q; Xu ZX; Xiong ML; Li HY; Xu MY; Luo SZ
    Neoplasma; 2022 Jul; 69(4):820-831. PubMed ID: 35532294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma.
    Zhang Y; Xu J; Zhang S; An J; Zhang J; Huang J; Jin Y
    Cell Physiol Biochem; 2018; 50(6):2124-2138. PubMed ID: 30415263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of lncRNA HOXA-AS2 Inhibits Viability, Migration and Invasion of Osteosarcoma Cells by miR-124-3p/E2F3.
    Wang L; Wang L; Zhang X
    Onco Targets Ther; 2019; 12():10851-10861. PubMed ID: 31853184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long Noncoding RNA HOXA-AS2 Promotes Papillary Thyroid Cancer Progression by Regulating miR-520c-3p/S100A4 Pathway.
    Xia F; Chen Y; Jiang B; Du X; Peng Y; Wang W; Huang W; Feng T; Li X
    Cell Physiol Biochem; 2018; 50(5):1659-1672. PubMed ID: 30384358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic long intervening noncoding RNA Linc00284 promotes c-Met expression by sponging miR-27a in colorectal cancer.
    You J; Li J; Ke C; Xiao Y; Lu C; Huang F; Mi Y; Xia R; Li Q
    Oncogene; 2021 Jun; 40(24):4151-4166. PubMed ID: 34050266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.